Australia is eagerly anticipating the arrival of retatrutide, a innovative dual GIP and GLP-1 receptor agonist , representing a potential advance in obesity treatment . Early study data have demonstrated https://giantescape3bike885133.wikipowell.com/7527481/emerging_medication_in_australia_a_promising_solution_for_reducing_body_weight